{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:50Z","timestamp":1791644630369,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacig.2026.100718","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:36:50Z","timestamp":1777073810000},"page":"100718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-4696","authenticated-orcid":false,"given":"William W.","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Iammatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle S.","family":"Mosnaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ledanois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"Sacks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100718_bib2","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jacig.2026.100718_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.iac.2016.03.004","article-title":"Biomarkers in severe asthma","volume":"36","author":"Wan","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2026.100718_bib4","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacig.2026.100718_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100718_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2026.100718_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2026.100718_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100718_bib11","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100718_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41533-023-00336-9","article-title":"Suboptimally controlled asthma in patients treated with inhaled ICS\/LABA: prevalence, risk factors, and outcomes","volume":"33","author":"Zhang","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jacig.2026.100718_bib13","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple therapy versus dual inhaler therapy for moderate-to-severe asthma: a systematic review and meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2026.100718_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","article-title":"Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study","volume":"8","author":"Kerstjens","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100718_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100718_bib16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","article-title":"Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology","volume":"199","author":"Beasley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100718_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid\u2013sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100718_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2026.100718_bib21","first-page":"1149","article-title":"Inhaled corticosteroid\u2013containing treatment escalation and outcomes for patients with asthma in a US health care organization","volume":"23","author":"Bengtson","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacig.2026.100718_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaip.2022.10.040","article-title":"Effect of stepping up to high-dose inhaled corticosteroids in patients with asthma: UK Database study","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:12:49Z","timestamp":1783131169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829326000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772829326000809"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100718","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100718"}}